Journal article
New insights into managing symptoms during statin therapy
Progress in cardiovascular diseases, Vol.62(5), pp.390-394
09/2019
DOI: 10.1016/j.pcad.2019.10.005
PMID: 31669768
Abstract
Symptoms during statin therapy are common and often attributed to statin intolerance. Recent data suggest few patients are truly intolerant to statins. Muscle symptoms are similar in statin and control groups in blinded treatment periods of clinical trials. The “nocebo” effect may occur during open-label statin treatment, when previously asymptomatic study participants report symptoms attributed to statin therapy, or during placebo-controlled trials. Most patients reporting statin intolerance can tolerate blinded moderate intensity statin therapy. In clinical practice the large majority of patients are willing to retry a statin, and of those who do, >80–90% successfully remain on statin therapy long-term. Emerging evidence from brain imaging studies and contemporary approaches to pain management suggests that building trust and managing patient expectations can minimize the “nocebo” effect in statin-treated patients.
Details
- Title: Subtitle
- New insights into managing symptoms during statin therapy
- Creators
- Jennifer G. Robinson - Departments of Epidemiology and Internal Medicine, Division of Cardiology, University of Iowa, United States of America
- Resource Type
- Journal article
- Publication Details
- Progress in cardiovascular diseases, Vol.62(5), pp.390-394
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.pcad.2019.10.005
- PMID
- 31669768
- ISSN
- 0033-0620
- eISSN
- 1532-8643
- Grant note
- DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100004334, name: Merck
- Language
- English
- Date published
- 09/2019
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984363620002771
Metrics
3 Record Views